Overview

A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib)

Status:
Active, not recruiting

Trial end date:
2025-01-15

Target enrollment:

Participant gender:

Summary

The main goal of this study is to evaluate the stability of molecular response (major and deep molecular response( MMR and DMR)) in patients with chronic myeloid leukemia (CML) with stable DMR after two-stage dose reduction phase and discontinuation treatment TKI: imatinib, nilotinib, dasatinib and bosutinib.

Phase:

Phase 2

Details

Lead Sponsor:

National Research Center for Hematology, Russia

Treatments:

Dasatinib
Imatinib Mesylate